Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Carbamic acid, [4-(4-oxocyclohexyl)phenyl]-, 1,1-dimethylethyl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

178163-65-0

Post Buying Request

178163-65-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

178163-65-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 178163-65-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,8,1,6 and 3 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 178163-65:
(8*1)+(7*7)+(6*8)+(5*1)+(4*6)+(3*3)+(2*6)+(1*5)=160
160 % 10 = 0
So 178163-65-0 is a valid CAS Registry Number.

178163-65-0Downstream Products

178163-65-0Relevant articles and documents

Pyrazolone-fused pyrimidine compound as well as preparation method and application thereof

-

Paragraph 0844; 0845; 0846; 0847, (2021/01/11)

The invention discloses a pyrazolone-fused pyrimidine compound as well as a preparation method and application thereof. The invention provides a pyrazolone-fused pyrimidine compound as shown in a formula II which is described in the specification. The pyrazolone-fused pyrimidine compound has better inhibitory activity on WEE1 kinase.

INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY

-

, (2019/08/26)

The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.

4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2

-

Page/Page column 56, (2010/11/03)

The present invention comprises compounds of Formula (I): wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 178163-65-0